General Description
Meprednisone is a synthetic glucocorticoid that is the 16β-methyl analogue of prednisone. The addition of a methyl group at the 16β position reduces mineralocorticoid activity and may alter pharmacokinetics. It is a prodrug that is converted in the liver to its active metabolite, meprednisolone (the 11β-hydroxy form). The molecule is structurally distinct from methylprednisolone, which has a 6α-methyl group.
Mechanism of Action
Meprednisone itself is inactive; it requires 11β-hydroxysteroid dehydrogenase type 1 reduction to meprednisolone, which then binds to cytoplasmic glucocorticoid receptors. The receptor-ligand complex modulates gene transcription, suppressing pro-inflammatory cytokines, inhibiting phospholipase A2, and reducing NF-κB activity. The 16β-methyl group reduces sodium-retaining activity compared to prednisone, resulting in less hypertension and edema at therapeutic doses.
Application
Meprednisone was indicated for inflammatory and autoimmune conditions such as rheumatoid arthritis, asthma, allergic disorders, and dermatologic diseases. It has a similar potency to prednisone but with slightly less mineralocorticoid effect. However, it is rarely used today, having been largely replaced by prednisone and methylprednisolone. The drug remains of historical interest as an example of 16β-substituted glucocorticoids.